11 citations
,
August 2017 in “Supportive care in cancer” This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
This review discusses various strategies to mitigate taxane-induced alopecia in cancer treatment, highlighting the potential of low-intensity ultrasound to reverse hair follicle damage by disrupting taxane-stabilized microtubules.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
25 citations
,
March 2018 in “Journal of oncology practice” This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.
2 citations
,
May 2016 in “Journal of Clinical Oncology” This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.
1 citations
,
May 2017 in “Journal of Clinical Oncology” This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.
April 2026 in “Scientific Reports” This study presents a new automated computer vision system to objectively measure periocular hair density changes in breast cancer patients undergoing chemotherapy, demonstrating high precision in tracking individual changes and potential as a reliable tool for future clinical trials.
July 2024 in “Journal of Investigative Dermatology” Scalp cooling may be less effective for women of color on certain chemotherapy treatments.
May 2024 in “Deleted Journal” This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.
October 2018 in “Annals of oncology” This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.
February 2017 in “Cancer Research” In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.
August 2026 in “Indonesian Journal of Global Health Research” This study reports that scalp cooling is 40%-90% effective in preventing chemotherapy-induced hair loss among breast cancer patients, particularly with taxane-based treatments, though some exhibited discontinuation due to mild side effects.
5 citations
,
January 2024 in “BMC Cancer” In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.
4 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Scalp cooling therapy is costly and often not covered by insurance, limiting access for low-income patients.
1 citations
,
January 2024 in “The Journal of Dermatology” In this study, Asian breast cancer patients undergoing taxane-based chemotherapy in the adjuvant treatment group reported significantly increased hair loss, higher melanin index, and more wrinkles compared to other treatments, while most neoadjuvant group patients saw hair loss reversed six months post-surgery.
September 2025 in “PubMed” In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.
This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.
2 citations
,
December 2013 in “Cancer Research” This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.
July 2026 in “IntechOpen eBooks” This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.
November 2025 in “npj Breast Cancer” In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.
3 citations
,
June 2011 in “Korean Journal of Clinical Oncology” This article discusses chemotherapy-induced alopecia and its significant psychological impact on cancer patients, noting that some may even refuse treatment due to fear of hair loss.
233 citations
,
March 2009 in “Journal of Clinical Oncology” In this study, among patients undergoing chemotherapy for breast or gynecologic cancers, smell and taste functions significantly decreased but largely recovered three months post-treatment, with taxane-based regimens causing more severe taste disturbances.
March 2026 in “Cancer Diagnosis & Prognosis” In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.
July 2025 in “Current Treatment Options in Oncology” This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.
2 citations
,
June 2024 in “JAAD reviews.” In this review, researchers summarize drugs associated with scarring or permanent hair loss, notably after chemotherapy and tyrosine kinase inhibitor treatments, emphasizing the need for stronger evidence and long-term follow-up studies, as current findings are mostly from case reports.
4 citations
,
March 2023 in “Current Oncology” This study reviews current methods and emerging approaches to prevent and treat chemotherapy-induced hair loss, reporting that evidence-based research is needed to validate effective strategies, which could enhance cancer patients’ quality of life and treatment compliance.
5 citations
,
January 2025 in “Cancers” This article discusses the importance of optimizing treatment protocols for chemotherapy-induced alopecia and reports no new clinical results; the authors emphasize improving patient outcomes and quality of life.
1 citations
,
May 2021 in “Scientific Reports” This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.
5 citations
,
September 2024 in “Journal of Clinical Medicine” This article reviews the pathophysiology of chemotherapy-induced alopecia and reports that scalp cooling can reduce hair loss by 50% in patients with early breast cancer receiving chemotherapy, without compromising survival or increasing scalp metastasis risk.